Drug intelligence / Profile preview

WSK-V102KF

Development stage: Unknown
Lead developer: West China Hospital of Sichuan University
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**WSK-V102KF** is an investigational combined COVID-19 and influenza vaccine being evaluated in adults aged 18 years and older. The registered Phase 1 study assesses its safety and immunogenicity as a single combination vaccination product relative to separate COVID-19 and influenza vaccines. The vaccine platform, antigen composition, influenza strain coverage, SARS-CoV-2 variant coverage, adjuvant, dosage form, and route of administration have not been publicly specified in the identified registry record.

Other names: Westvac COVID-19 and Influenza Vaccine威斯克新冠流感疫苗

Targets

SARS-CoV-2 spikeHA (Hemagglutinin)

Beyond the preview

Go deeper on WSK-V102KF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSK-V102KF.

Explore the full profile